Julie Marie Vose

机构：Nebraska Medical Center, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center · ORCID：0000-0003-1015-7434

发表论文 912 篇 · 总被引 59722 次 · h-index 111

代表论文

• Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study (2024 · The Lancet Haematology · 被引 166)
• Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium (2024 · Journal of Clinical Oncology · 被引 82)
• Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study (2024 · Blood · 被引 23)
• NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 (2025 · Journal of the National Comprehensive Cancer Network · 被引 21)
• 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma (2024 · Blood · 被引 17)
• EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL. (2024 · Journal of Clinical Oncology · 被引 10)